Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 3/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.64 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.54 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.54 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419258 | 0.88 | METAP1 (0.67) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL14306761 | 0.86 | METAP1 (0.72) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL14159089 | 0.85 | CYP24A1 (0.69) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL8874844 | 0.84 | METAP1 (0.65) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL6272399 | 0.84 | METAP1 (0.65) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL8596909 | 0.84 | METAP1 (0.65) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL29130805 | 0.84 | METAP1 (0.68) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL30715899 | 0.84 | METAP1 (0.68) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL8596536 | 0.82 | METAP1 (0.69) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL8874769 | 0.82 | METAP1 (0.69) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387254-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX LLC | 2014-10-02 | — | — | US | disclosed |
| US-8680315-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX, LLC (US) | 2014-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | ABCB1, ABCB11, DNPEP | METAP1 574/4885CYP19A1 1059/4885CYP24A1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.